PROCEPT BioRobotics公司在推进其前列腺癌治疗项目上取得重要进展,已顺利完成Water IV临床研究的患者招募工作。同时,公司获得了美国食品药品监督管理局(FDA)对其研究性器械豁免(IDE)的扩大批准,为该项目的进一步临床开发铺平了道路。
PROCEPT BioRobotics公司在推进其前列腺癌治疗项目上取得重要进展,已顺利完成Water IV临床研究的患者招募工作。同时,公司获得了美国食品药品监督管理局(FDA)对其研究性器械豁免(IDE)的扩大批准,为该项目的进一步临床开发铺平了道路。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.